Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.
Paysign, Inc. reports developments in patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing for the life sciences industries. The company operates at the intersection of fintech and healthcare, serving plasma, pharmaceutical and life sciences customers with payment and program-management technologies.
Recurring updates cover earnings results, patient affordability growth, pharmaceutical copay program performance, claims-processing activity, plasma donor compensation revenue, and SaaS engagement technologies for donor and program management. Company announcements also discuss Dynamic Business Rules for mitigating copay accumulators and maximizers, physical, virtual, mobile and bank-based payment capabilities, reporting and analytics, and investor conference participation.
Paysign (NASDAQ:PAYS) announced it will present at Planet MicroCap Las Vegas 2026, held June 16-18, 2026 at the Bellagio Resort & Casino. CFO Jeff Baker is scheduled to present on Wednesday, June 17 at 11:30 a.m. Pacific time.
Investors can visit the event website for details, registration, agenda and webcasts.
Paysign (NASDAQ:PAYS), a provider of patient affordability and donor compensation payment solutions, will present at the 20th Annual Barrington Research Virtual Spring Investment Conference on May 27, 2026. CFO Jeff Baker will hold one-on-one presentations, and investors can visit the event website for registration details.
Paysign (NASDAQ:PAYS) reported strong first quarter 2026 results, with revenue of $28.04 million, up 50.8% year over year. Pharma revenue rose 81.9% to $15.68 million and plasma revenue grew 24.9% to $11.75 million.
Operating margin expanded to 23.8% from 13.4%, while net income increased 110.3% to $5.44 million, or $0.09 per diluted share. Adjusted EBITDA rose 113.4% to $10.59 million. Paysign ended the quarter with $20.55 million in unrestricted cash and no bank debt. Full-year 2026 guidance calls for revenue of $106.5–$110.5 million, 30–35% growth, and net income of $13–$16 million.
Paysign (NASDAQ: PAYS) will host its first quarter 2026 earnings call at 5:00 p.m. ET on Tuesday, May 12, 2026. The company provided dial-in numbers, a webcast link, and replay details; the replay is available until August 12, 2026. Financial professionals wishing to ask questions must register by 5:00 p.m. ET on Friday, May 8, 2026 via email.
Paysign (NASDAQ: PAYS) reported strong 2025 results: $82.02M revenue (+40.5%), net income of $7.55M and Adjusted EBITDA $19.94M (+107.3%). Pharma revenue grew 167.8% and patient affordability programs rose to 131. Company exited 2025 with $21.07M unrestricted cash, $143.92M restricted cash and zero debt. 2026 guidance targets $106.5M–$110.5M revenue and $30M–$33M adjusted EBITDA.
Paysign (NASDAQ: PAYS) will host its fourth quarter and full year 2025 earnings call on Tuesday, March 24, 2026 at 5:00 p.m. ET. Investors can join via U.S. and international dial-ins or a live webcast. Replay is available through June 24, 2026.
Financial professionals who wish to ask questions must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, March 20, 2026.
Paysign (NASDAQ: PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference, held February 3-4, 2026, in a virtual format. The conference features one-on-one and small-group meetings with emerging companies across technology, industrial growth and consumer sectors. Paysign’s CFO Jeff Baker will host one-on-one investor meetings on Tuesday, February 3, 2026. Investors interested in attending are instructed to contact their Oppenheimer representative to register.
Paysign (NASDAQ: PAYS) reported 2025 patient affordability results showing material growth and measurable savings. The company exited 2025 with 131 active programs (added 55 in 2025), a >70% increase versus 2024, and supported >840,000 unique patients. Paysign said its Dynamic Business Rules feature identifies impacted claims on first fill with 97% accuracy and helped mitigate copay maximizers, saving pharmaceutical program sponsors more than $325 million in 2025 (an increase of >200% from 2024). Paysign also reported assisting clients in delivering more than $950 million toward prescription fulfillment expenses in 2025.
The release frames these metrics as evidence of expanded healthcare presence and enhanced value delivery to patients and pharmaceutical sponsors.
Paysign (NASDAQ: PAYS) will present at the 17th Annual Southwest IDEAS Investor Conference in Dallas, Texas on November 19–20, 2025. The invitation-only conference connects public companies with institutional investors via one-on-one and group meetings.
Paysign's CFO Jeff Baker will present on Thursday, November 20, 2025 and is available for one-on-one meetings during the event.
Paysign (NASDAQ: PAYS) reported record Q3 2025 results with $21.60M revenue, up 41.6% year-over-year, and net income of $2.22M (diluted EPS $0.04), up 54.2%. Adjusted EBITDA was $5.04M (23.3% margin), up 78.1%. Pharma patient affordability revenue grew 141.9% to $7.92M with 105 active programs at quarter end (118 at Oct 31). Plasma revenue rose 12.4% to $12.86M with 595 centers. Ended Q3 with $7.53M unrestricted cash and zero bank debt; unrestricted cash was reduced by timing on $9.36M passthrough claim items. Updated 2025 guidance: revenue $80.5M–$81.5M, net income $7.0M–$8.0M, Adjusted EBITDA $19M–$20M.